Preprint
Review

This version is not peer-reviewed.

Anesthetic and Sedative Effects on Echocardiographic Parameters in Rat Models of Cardiomyopathy: A Critical Review

Submitted:

02 November 2026

Posted:

04 November 2026

You are already at the latest version

Abstract
Cardiomyopathies represent a heterogeneous group of diseases that lead to functional and structural impairment of the myocardium, frequently culminating in heart failure. Due to ethical and technical constraints inherent to human studies, rat models have become indispensable in experimental cardiology. Transthoracic echocardiography represents one of the most commonly used methods for assessing cardiac structure and function in experimental rat models of cardiomyopathy, due to its accessibility, non-invasiveness, ease of use, safety and cost-effectiveness. Almost all echocardiographic examinations in rats require a certain level of pharmacological sedation or general anesthesia to immobilize the animal and reduce motion-induced artifacts. A review of the literature reveals that only a few anesthetics are used in experimental practice. By far the two most prevalent choices are isoflurane and the ketamine-xylazine combination. Less frequently used are pentobarbital, the tiletamine-zolazepam combination, sevoflurane, and acepromazine. However, the interpretation of echocardiographic findings in experimental animals can be significantly biased by the effects of anesthesia primarily on the autonomic nervous system and cardiac contractility. Therefore the choice of anesthetic or sedative protocol represents an important, yet insufficiently standardized, methodological variable in the echocardiographic assessment of rat models of cardiomyopathy. Here we discuss the bias introduced by the use of sedatives/anesthetics when performing echocardiography in different rat models of experimental cardiomyopathy.
Keywords: 
;  ;  ;  ;  ;  ;  

1. Introduction

Cardiomyopathies represent a heterogeneous group of diseases that lead to functional and structural impairment of the myocardium, frequently culminating in heart failure. Due to ethical and technical constraints inherent to human studies, rat models have become indispensable in experimental cardiology. Rats (Rattus norvegicus) are particularly well-suited for this purpose due to the physiological similarity of their myocardium to that of humans, the relative ease of genomic manipulation and the availability of diverse strains for pharmacological testing. Selecting an appropriate model constitutes the first critical step in the design of a preclinical study, ensuring that the experimental research is both reliable and translatable [1,2].

1.1. Echocardiography as the Primary In Vivo Phenotyping Tool

A detailed characterization of cardiac damage in rat models constitutes a prerequisite for understanding and clarifying the mechanisms underlying the development of cardiomyopathies, as well as for identifying potential novel therapeutic targets. This represents a critical step for translation into studies involving larger animal models, and subsequently into clinical research [3]. Left ventricular ejection fraction (LVEF) is the most widely accepted parameter for the assessment of cardiac function; however, a measurable decline in LVEF typically becomes apparent only once significant morphological damage to the myocardium has already occurred. Although myocardial strain imaging and cardiac magnetic resonance are considerably more sensitive and specific techniques, capable of detecting subclinical alterations in myocardial performance prior to any decline in LVEF, transthoracic echocardiography remains the gold standard for the assessment of cardiac morphology and function, both in experimental research and in clinical cardiology practice due to its accessibility, non-invasiveness, ease of use, safety and cost-effectiveness [4]. Technically, application in rats requires specialized equipment adapted to the small cardiac size and rapid heart rate (300–450 beats per minute); current guidelines recommend the use of ultra-high-frequency micro-ultrasound systems [5].

1.2. Choice of Anesthetic/Sedative as a Critical Confounding Factor

Almost all echocardiographic examinations in rats require a certain level of chemical sedation or general anesthesia to immobilize the animal and reduce motion-induced artifacts. Current recommendations [6] support the use of anesthesia as the primary approach to echocardiographic imaging in rodents, as anesthesia facilitates standardization and reduces variability caused by movement and sympathetic activation. However, this entails a significant methodological problem: most anesthetics exhibit dose-dependent effects on cardiac function and/or vascular tone, which may influence echocardiographic findings. The potential effect of anesthesia is not uniform, but rather depends also on the underlying pathological state of the animal [3].When selecting the anesthetic and its dose for echocardiographic examination in rats, several factors should be taken into account: the parameters being measured, the duration and number of repeated imaging sessions, the physiological parameters of the individual animal, the disease model, and its interaction with the anesthetic agent itself.

1.3. Aim and Methodology of the Review

The aim of this critical review is to synthesize and critically evaluate the existing scientific literature on the influence of anesthetic and sedative agent selection on echocardiographic parameters in rat models of cardiomyopathy, with particular emphasis on how this methodological variable may affect the interpretation of the cardiovascular phenotype in preclinical research. More specifically, the aim of this work is to provide a systematized overview of the most commonly used rat models of cardiomyopathy, to analyze the documented effects of individual anesthetic and sedative agents on standard echocardiographic parameters, to examine the methodological factors that further modify the influence of anesthesia and to highlight patterns of heterogeneity in anesthetic protocols across the existing literature, as well as to formulate recommendations for the standardization of reporting and anesthetic selection in future studies.
This paper is conceived as a narrative/critical review. The inclusion criteria applied during the literature review were original experimental studies and previous review articles published in English, which used the rat (Rattus norvegicus) as the experimental model and which explicitly specified the anesthetic/sedative protocol used and performed an echocardiographic assessment. No restriction was imposed with regard to the year of publication.

2. Rat Models of Cardiomyopathy

Based on the mechanism by which cardiomyopathy is induced, models can be classified into toxic, genetic/spontaneous, surgical and metabolic [7] (Table 1).
Toxic models are drug-induced models. Pharmacological induction represents one of the most common approaches for developing cardiomyopathy models due to its relative simplicity and reproducibility of results. Doxorubicin, an anthracycline cytostatic agent, is one of the most frequently employed agents for the induction of dilated cardiomyopathy [8]. The most important mechanisms responsible for the development of doxorubicin-induced cardiotoxicity are oxidative stress, apoptosis, dysregulation of calcium homeostasis, disruption of energy homeostasis, and extracellular matrix remodeling [9]. Protocols differ with respect to dosage and route of administration. Dosing regimens range from a single high dose to multiple repeated low doses, with intraperitoneal or intravenous injection representing the most common routes of administration. Cardiotoxicity is assessed by echocardiography or nuclear imaging, serum troponin and BNP levels, and histopathological analysis [8]. Isoproterenol, a non-selective beta-adrenergic agonist, when administered by infusion at high doses, induces an acute ischemic-necrotic myocardial lesion due to increased oxygen consumption, thereby simulating hypertrophic cardiomyopathy [10]. Pulmonary hypertension can be induced by monocrotaline (MCT), which triggers vascular lesions, leading to pressure overload and hypertrophy of the right ventricle [11,12]
A widely studied genetic model, spontaneously hypertensive rats (SHR), develop cardiac hypertrophy and subsequent heart failure as a consequence of genetically determined hypertension, without requiring surgical or pharmacological intervention. This makes them ideal for studies of long-term cardiac remodeling, and the model is useful for elucidating underlying causes and potential novel therapies. In addition, other genetically modified rat strains provide direct insight into the molecular mechanisms of specific types of cardiomyopathy associated with mutations found in humans [13]. Obese ZSF1 rats (O-ZSF1) represent a model of heart failure with preserved ejection fraction (HFpEF). ZSF1 rats are hybrids, a cross between a female Zucker Diabetic Fatty (ZDF) rat and a male Spontaneously Hypertensive Heart Failure (SHHF) rat, carrying two mutant leptin receptor alleles, faithfully reproducing the major phenotypic characteristics of HFpEF, and thus represent a widely applied model for the study of cardiometabolic disorders and HFpEF [14].
Surgical models include pressure-overload models, which simulate clinical conditions such as arterial hypertension and aortic stenosis, leading to left ventricular hypertrophy and eventual heart failure. The most commonly used method in mice, but also in rats, is aortic ligation or transverse aortic constriction (TAC). In the ventral aortic ligation model, marked concentric hypertrophy has been observed, characterized by thickening of the left ventricular walls [15].
Streptozotocin-induced diabetic cardiomyopathy represents a metabolic model of rat cardiomyopathy. Streptozotocin chemically induces type 1 diabetes through selective destruction of pancreatic beta-cells, with secondary development of diabetic cardiomyopathy. The resulting myocardial dysfunction occurs independently of coronary artery disease or hypertension, and is closely associated with oxidative stress, inflammation, and mitochondrial dysfunction. This model is frequently combined with other toxic models to investigate comorbidities [16].

3. Pharmacology of Anesthetic and Sedative Agents Commonly Used in Rat Echocardiography

Despite the large number of available anesthetics, a review of the literature has shown that a relatively small number of them are used in practice. By far the two most prevalent choices are isoflurane and the ketamine-xylazine combination. In addition to these, pentobarbital, the tiletamine-zolazepam combination, sevoflurane, and acepromazine, either alone or in combination with ketamine are used less frequently. Isoflurane and sevoflurane are administered by inhalation, while all others are administered via intraperitoneal or intramuscular injection (Table 2).
Isoflurane and sevoflurane are halogenated volatile anesthetics that induce dose-dependent depression of both the cardiovascular and respiratory systems. They act as positive allosteric modulators of GABA-A receptors, agonists of glycine receptors and potassium channels, and antagonists of glutamate receptors. They are well suited for easy maintenance of anesthesia and rapid reversibility. Isoflurane is used more frequently than sevoflurane due to its lower cost, greater availability, and relatively straightforward titration [17].
Ketamine is an NMDA receptor antagonist. It exerts a complex effect on the heart, which is particularly relevant when used for echocardiography in rats with cardiomyopathy. In relatively healthy animals, ketamine predominantly induces central stimulation of the sympathetic system and stimulates cardiac performance. In animals with severely compromised cardiac function, however, the sympathetic reserve may be insufficient, allowing the drug's negative inotropic effects to become manifest. In combination with xylazine, ketamine produces a decline in heart rate and cardiac output [18,19].Tiletamine is a dissociative NMDA receptor antagonist, pharmacodynamically similar to ketamine. Compared with ketamine, it is more potent and longer-acting, providing analgesia and immobilization. It is available exclusively in a fixed combination with zolazepam. In rats, this combination induces a significantly higher cardiac function index along with elevated blood pressure [20].
Xylazine is an alpha-2 adrenergic receptor agonist that induces sedation, analgesia, and muscle relaxation through activation of central nervous system receptors, with bradycardia and reduced cardiac output representing its characteristic cardiovascular effects. When combined with ketamine, the role of xylazine is to counteract ketamine-induced muscle rigidity and sympathetic activation, particularly with respect to cardiac function [6].
Pentobarbital belongs to the barbiturate class. It acts by enhancing GABA-mediated chloride currents at the GABA-A receptor, thereby inducing generalized depression of neuronal activity; the resulting hypotension is attributed both to depression of central sympathetic activity and to direct depression of myocardial contractility. It was frequently used in older studies but is rarely employed today owing to its pronounced adverse effects on the respiratory and cardiovascular systems. (20)
Zolazepam belongs to the benzodiazepines, a class of drugs that act as positive allosteric modulators of GABA-A receptors. It produces muscle relaxation and tranquilization, thereby complementing the dissociative and analgesic properties of tiletamine within the combined formulation. Other benzodiazepines, such as midazolam and diazepam, can be combined with ketamine to contribute to sedation and muscle relaxation of the animal. They have a very weak to negligible negative effect on the cardiovascular system [20].
Acepromazine is a phenothiazine tranquilizer that produces sedation primarily through antagonism of central dopaminergic receptors and causes peripheral α₁-adrenergic blockade, resulting in vasodilation and a reduction in arterial blood pressure. It is used primarily as a sedative and preanesthetic agent rather than as an anesthetic, and may be combined with injectable anesthetic agents such as ketamine as part of a balanced anesthetic protocol [21].

4. Effects on Echocardiographic Parameters

The interpretation of echocardiographic findings in experimental animals can be significantly complicated by the fact that anesthesia itself alters several physiological parameters that directly affect echocardiographic measurements. Anesthetics can alter heart rate, myocardial contractility, peripheral vascular resistance, preload and afterload, body temperature, and respiratory pattern. Changes in these parameters can affect ejection fraction (EF), fractional shortening (FS), left ventricular dimensions, stroke volume (SV), cardiac output (CO), as well as parameters of systolic and diastolic function obtained through Doppler and tissue Doppler examination. For this reason, differences in the anesthetic used may represent a significant methodological factor and a potential source of variability between experimental studies. The most commonly used protocols for echocardiographic examination in rats include inhalational isoflurane and injectable combinations, primarily ketamine/xylazine [6,22].
The most pronounced effects of anesthesia have been described for parameters of systolic function, measured through EF and fractional shortening FS. In a study directly comparing pentobarbital, isoflurane, and the ketamine-xylazine combination in rats, pentobarbital was associated with higher EF and FS values compared with isoflurane and ketamine/xylazine. At the same time, ketamine/xylazine produced a more pronounced reduction in heart rate and cardiac output [22]. In another study directly comparing ketamine-xylazine and isoflurane in healthy rats and rats with chronic aortic regurgitation, left ventricular dimension and ejection fraction values were not altered in healthy animals, whereas in the aortic regurgitation group, left ventricular dimension values were reduced under the influence of the chosen anesthetic [23]. These findings indicate that a direct comparison of EF or FS between different experiments is not justified when animals are examined under different anesthetic protocols, and also that the sensitivity of systolic parameters to anesthetic choice is conditioned by the underlying pathological state of the myocardium.
Diastolic Doppler parameters proved to be the most sensitive to the type of anesthesia. Mitral diastolic Doppler parameters, early [E] and late atrial [A] filling waves, were affected by both types of anesthesia, ketamine-xylazine and isoflurane, in both the healthy animals and the aortic regurgitation group [23].
End-diastolic diameter (EDD) and end-systolic diameter (ESD) of the left ventricle also show sensitivity to anesthetic administration, minimal in healthy animals, but becoming pronounced in the presence of structural pathology. In healthy rats, when comparing four anesthetic protocols (isoflurane, pentobarbital, ketamine/xylazine, and tiletamine/zolazepam), left ventricular diastolic dimension values were lower with pentobarbital and tiletamine/zolazepam compared with isoflurane or ketamine/xylazine [24].
Values of heart rate, stroke volume, and cardiac output show variability when different anesthetics are used. In a comparative study involving four protocols, heart rate was highest and stroke volume lowest with pentobarbital, while blood pressure values were significantly higher in the tiletamine/zolazepam group compared with the other groups [24,25].
The anesthetic effect may also be relevant for the assessment of hypertrophy. Although structural parameters, such as interventricular septal and left ventricular wall thickness, are generally more stable than functional parameters, changes in preload and chamber dimensions can influence their interpretation. In models of hypertension-induced left ventricular hypertrophy, echocardiography is therefore often performed under strictly controlled isoflurane concentration and constant body temperature [26].

5. Discussion

Anesthesia is necessary to ensure immobilization of the animal, reduce motion-induced artifacts, and enable reproducible acquisition of echocardiographic images. However, anesthetics simultaneously alter heart rate, blood pressure, preload and afterload, myocardial contractility, peripheral vascular tone, and respiratory physiology. Consequently, changes in the recorded echocardiographic parameters may not fully reflect the characteristics of the underlying cardiomyopathy model and the experimental protocol, but may instead represent the result of the pharmacological action of the anesthetic, often in interaction with the animal's disease state.
The effect of anesthetics on echocardiographic parameters is particularly significant in models of cardiomyopathy, in which hemodynamic reserves are already compromised. In a healthy myocardium, certain changes in heart rate or vascular tone may be relatively well compensated, whereas in a heart with systolic or diastolic dysfunction, administration of a pharmacological substance can lead to considerably more pronounced changes. For this reason, the effect of an anesthetic cannot be considered in isolation from the underlying disease phenotype.
The same anesthetic protocol that has proven reliable in validation studies on healthy animals does not guarantee equal reliability when applied to models of advanced cardiomyopathy, as some studies have shown, not only in rats but also in mice [23,27,28]. This finding is rarely acknowledged as a limitation in primary experimental studies, even though it suggests that the same animal, based on its echocardiographic parameters, may be classified differently depending on the anesthetic protocol applied. In other words, at least part of the inconsistency observed in published findings on the same cardiomyopathy model may stem from differences in anesthetic protocols, rather than from biological differences between the animals studied or variations in experimental execution. This also raises the question of whether healthy animals constitute an appropriate control group relative to the experimental group consisting of animals with cardiomyopathy.
A further issue is that, despite the existence of dozens of published rat models of cardiomyopathy, the number of anesthetic protocols actually used in practice is small. Two protocols dominate, isoflurane and the ketamine-xylazine combination, while pentobarbital, tiletamine-zolazepam, and acepromazine are used considerably less often, and in more recent times, hardly at all (Table 3). Due to their different pharmacological mechanisms of action, these agents have different effects on the cardiovascular system, and consequently on echocardiographic parameters. The advantage of isoflurane lies in the ability to continuously and relatively precisely control the depth of anesthesia, as well as to rapidly adjust its concentration. For this reason, inhalational anesthetics are often preferred when the goal is repeated echocardiographic assessment during longitudinal follow-up. ESC recommendations for rodent echocardiography list isoflurane among the most commonly used regimens, noting that ketamine/xylazine may exert a more pronounced cardiodepressive effect [6,29]. On the other hand, ketamine-xylazine combination offers practical advantages and may be particularly useful when the goal is to assess diastolic function in certain models[22]. Nevertheless, even within these two dominant protocols, direct comparative literature systematically comparing their effects within the same cardiomyopathy model remains quite limited. Beyond the heterogeneity of the studies themselves, which directly complicates the synthesis of the literature and the comparison of results between experiments, an additional issue is that a large number of published studies fail to report the complete anesthetic protocol.
Furthermore, the key question is not merely whether an anesthetic alters an echocardiographic parameter, but to what extent this effect depends on the underlying cardiomyopathy model. As highlighted in the section on models, different types of cardiomyopathy differ substantially with respect to which ventricle and which type of load predominates. The only claim that has been directly experimentally confirmed concerns the HFpEF/ZSF1 model, in which the administration of ketamine-xylazine was shown to reveal diastolic dysfunction that isoflurane, owing to its effects, masks.(27). Although model-specific empirical comparisons of anesthetics are largely lacking in the literature, the pharmacological mechanism and hemodynamic architecture of each model suggest a framework for more informed anesthetic selection. In toxic/pharmacological models (doxorubicin, isoproterenol), ketamine administered alone in the isoprenaline model carries a theoretical risk of interaction with the beta-adrenergic mechanism underlying the disease itself, making isoflurane or the ketamine-xylazine combination potentially safer choices. Doxorubicin-induced cardiotoxicity is characterized by a progressive, diffuse decline in contractility resulting from oxidative stress and mitochondrial dysfunction. This means that for this model, the key outcome is typically systolic function followed longitudinally over weeks to months, rather than acute diastolic dysfunction as in the HFpEF model [9]. Thus, for the doxorubicin model, a reasonable recommendation would be to use the same, predefined protocol, whether the ketamine-xylazine combination or isoflurane, consistently across all time points of the same study, with explicit reporting of the dose administered. A direct comparative study is warranted to determine which protocol is objectively more appropriate for this specific model. In pressure-overload models, monocrotaline model, agents that further increase vascular resistance, such as ketamine administered alone, should be used with caution, as they may theoretically accentuate the already existing afterload, whereas isoflurane, although it reduces afterload, requires careful titration so as not to mask the degree of compensatory hypertrophy, due to the need for surgical precision during the procedure [11]. In volume-overload models, such as aortic regurgitation or arteriovenous fistula, where the predominant variable is elevated preload and venous return, a protocol that maintains a stable hemodynamic status is required, although this area warrants further validation [23]. In SHR rats, in which genetically determined, chronically elevated sympathetic activity represents the underlying pathophysiological mechanism of hypertension, administration of ketamine-xylazine drastically suppresses sympathetic tone, thereby masking, as confirmed both theoretically and experimentally, precisely the mechanism that renders this model clinically relevant [30]. For this reason, isoflurane is well suited and most commonly used for echocardiographic imaging in SHR rats [31].
Unlike human cardiology, no universally accepted guidelines or cutoff values for EF or FS exist in experimental rat models that would independently define heart failure. Even baseline EF and FS values are not strictly defined, as they depend on strain, measurement method and, above all, the anesthetic protocol [6,29]. Instead of an absolute cutoff, standard practice in the literature relies on relative comparison, each study compares the experimental group with its own, simultaneously imaged control group, under the same anesthetic protocol. Heart failure in rats is therefore diagnosed through a combination of echocardiographic and hemodynamic indicators, biochemical analyses, and histopathological findings. This absence of standardization further reinforces the methodological importance of maintaining a consistent anesthetic protocol within each individual study.

5. Conclusions

This critical review has shown that the choice of anesthetic or sedative protocol represents an important, yet insufficiently standardized, methodological variable in the echocardiographic assessment of rat models of cardiomyopathy. The choice of anesthetic influences the absolute values of the measured parameters, and can even alter the diagnostic conclusion of the study itself. The analysis of the available literature indicates that the effect of anesthesia is not uniform, but rather depends on the pharmacological mechanism of action of the anesthetic itself, on the type of echocardiographic parameter being measured, and, most importantly, on the underlying pathological state of the myocardium, i.e., the cardiomyopathy model. In addition, this review has highlighted a chronic lack of standardized reporting of anesthetic protocols in published studies, as well as the absence of universally accepted reference values for echocardiographic parameters in rats, both of which further complicate the comparison of results between studies.
An anesthetic that is optimal for performing a technically high-quality examination is not necessarily optimal for assessing a particular aspect of cardiac function. An important consideration is whether a given anesthetic preserves the physiological state relevant to the research question at hand. From all of the above, the central conclusion emerges that the choice of anesthetic should not be regarded merely as a technical component of the protocol, based solely on its ability to provide adequate sedation and immobilization. It should instead be regarded as an active experimental variable, the selection of which should take into account the cardiomyopathy model used in the experimental animals and the echocardiographic parameters being measured, as well as standardize the route of administration and dose, depending on the anesthetic used. Finally, the confounding effects of anesthesia on cardiac function in experimental models of cardiomyopathy, as evaluated by echocardiography, should be discussed in a separate section, as they represent a serious limitation of experimental studies.

6. Future Directions

Based on the synthesized findings, several practical recommendations emerge for researchers planning echocardiographic assessment of rat models of cardiomyopathy:
  • Priority should be given to systematic studies that directly compare the most commonly used anesthetic protocols, primarily ketamine-xylazine and isoflurane, within the same cardiomyopathy model.
  • Adoption of explicit guidelines for reporting the anesthetic protocol in rat echocardiography studies, which would mandatorily include the exact dose, route of administration, and depth and duration of anesthesia. This would significantly improve the possibility of comparison and meta-analytic synthesis of data between independent studies.
  • Development of a conceptual framework for anesthetic selection according to the type of hemodynamic structure characteristic of a given model.
  • Further research should include the validation of techniques that reduce or eliminate the need for anesthesia, including echocardiography in awake animals or the application of telemetry systems for continuous hemodynamic monitoring.

Author Contributions

Conceptualization: N.J.-Ž. and V.P., writing: V.P.;Critical editing: N.J.-Ž.,M.K. and M.J. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Ministry of Science, Technological Development and Innovation of Serbia, grant number 451-03-34/2026-03/200110.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Acknowledgments

During the preparation of this manuscript, the author(s) used Claude, the free version, to improve the clarity and readability of the English language, and the Paperpile reference manager. The authors have reviewed and edited the output and take full responsibility for the content of this publication.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Carll, A.P.; Willis, M.S.; Lust, R.M.; Costa, D.L.; Farraj, A.K. Merits of non-invasive rat models of left ventricular heart failure. Cardiovasc Toxicol. 2011, 11(2), 91–112. [Google Scholar] [CrossRef] [PubMed]
  2. Bader, M. Rat models of cardiovascular diseases. Methods Mol. Biol. 2010, 597, 403–14. [Google Scholar] [CrossRef] [PubMed]
  3. Schwarz, E.R.; Pollick, C.; Dow, J.; Patterson, M.; Birnbaum, Y.; Kloner, R.A. A small animal model of non-ischemic cardiomyopathy and its evaluation by transthoracic echocardiography. Cardiovasc Res. 1998, 39(1), 216–23. [Google Scholar] [CrossRef] [PubMed]
  4. Authors/Task Force Members; McDonagh, T.A.; Metra, M.; Adamo, M.; Gardner, R.S.; Baumbach, A.; et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail 2022, 24(1), 4–131. [Google Scholar] [CrossRef]
  5. Silva, J.; Azevedo, T.; Ginja, M.; Oliveira, P.A.; Duarte, J.A.; Faustino-Rocha, A.I. Realistic Aspects of Cardiac Ultrasound in Rats: Practical Tips for Improved Examination. 2024, 10(9). [Google Scholar] [CrossRef] [PubMed]
  6. Zacchigna, S.; Paldino, A.; Falcão-Pires, I.; Daskalopoulos, E.P.; Dal Ferro, M.; Vodret, S.; et al. Towards standardization of echocardiography for the evaluation of left ventricular function in adult rodents: a position paper of the ESC Working Group on Myocardial Function. Cardiovasc Res. 2021, 117(1), 43–59. [Google Scholar] [CrossRef] [PubMed]
  7. Ponzoni, M.; Coles, J.G.; Maynes, J.T. Rodent Models of Dilated Cardiomyopathy and Heart Failure for Translational Investigations and Therapeutic Discovery. Int. J. Mol. Sci. [Internet] 2023, 24(4). [Google Scholar] [CrossRef] [PubMed]
  8. Nakahara, T.; Tanimoto, T.; Petrov, A.D.; Ishikawa, K.; Strauss, H.W.; Narula, J. Rat Model of Cardiotoxic Drug-Induced Cardiomyopathy. Methods Mol. Biol. 2018, 1816, 221–32. [Google Scholar] [CrossRef] [PubMed]
  9. Sharma, S.; Parashar, M.; Lal, K.; Naik, M.; Tanwar, S.S. Doxorubicin-Induced Cardiotoxicity: Comprehensive Pathway Insights and Advanced Preclinical Therapeutics. J. Appl. Toxicol. 2026, 46(6), 1801–37. [Google Scholar] [CrossRef] [PubMed]
  10. Houson, H.; Hedrick, A.; Awasthi, V. Drug-induced cardiomyopathy: Characterization of a rat model by [F]FDG/PET and [Tc]MIBI/SPECT. Anim. Model Exp. Med. 2020, 3(4), 295–303. [Google Scholar] [CrossRef] [PubMed]
  11. Krstic, A.M.; Jones, T.L.M.; Power, A.S.; Ward, M.L. The Monocrotaline Rat Model of Right Heart Disease Induced by Pulmonary Artery Hypertension. Biomedicines [Internet] 2024, 12(9). [Google Scholar] [CrossRef] [PubMed]
  12. Jakovljevic Uzelac, J.; Djukic, T.; Mutavdzin, S.; Stankovic, S.; Labudovic Borovic, M.; Rakocevic, J.; et al. The influence of subchronic co-application of vitamins B6 and folic acid on cardiac oxidative stress and biochemical markers in monocrotaline-induced heart failure in male Wistar albino rats. Can. J. Physiol. Pharmacol. 2020, 98(2), 93–102. [Google Scholar] [CrossRef] [PubMed]
  13. Houser, S.R.; Margulies, K.B.; Murphy, A.M.; Spinale, F.G.; Francis, G.S.; Prabhu, S.D.; et al. Animal models of heart failure: a scientific statement from the American Heart Association. Circ. Res. 2012, 111(1), 131–50. [Google Scholar] [PubMed]
  14. Büttner, P.; Augstein, A.; Abdellatif, M.; Lourenço, A.; Leite-Moreira, A.; Falcão-Pires, I.; et al. Lean ZSF1 rats in basic research on heart failure with preserved ejection fraction. ESC Heart Fail 2025, 12(2), 1474–8. [Google Scholar] [CrossRef] [PubMed]
  15. Ku, H.C.; Lee, S.Y.; Wu, Y.K.A.; Yang, K.C.; Su, M.J. A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats. J. Vis. Exp. [Internet] 2016, 118. [Google Scholar]
  16. Becher, P.M.; Lindner, D.; Fröhlich, M.; Savvatis, K.; Westermann, D.; Tschöpe, C. Assessment of cardiac inflammation and remodeling during the development of streptozotocin-induced diabetic cardiomyopathy in vivo: a time course analysis. Int. J. Mol. Med. 2013, 32(1), 158–64. [Google Scholar] [CrossRef] [PubMed]
  17. Hendrix, J.M.; Kramer, J. Anesthesia Inhalation Agents and Their Cardiovascular Effects. In StatPearls; StatPearls Publishing: Treasure Island (FL), 2025. [Google Scholar]
  18. Reyes Toso, C.F.; Linares, L.M.; Rodríguez, R.R. [Cardiovascular effects of ketamine anesthesia in rats treated with enalapril and propranolol]. Medicina (B Aires) 1992, 52(3), 240–4. [Google Scholar] [PubMed]
  19. Byrne, A.J.; Tomlinson, D.R.; Healy, T.E. Ketamine and sympathetic mechanisms in cardiac and smooth muscle. Acta Anaesthesiol. Scand. 1982, 26(5), 479–84. [Google Scholar] [CrossRef] [PubMed]
  20. Saha, D.C.; Saha, A.C.; Malik, G.; Astiz, M.E.; Rackow, E.C. Comparison of cardiovascular effects of tiletamine-zolazepam, pentobarbital, and ketamine-xylazine in male rats. J. Am. Assoc. Lab Anim. Sci. 2007, 46(2), 74–80. [Google Scholar] [PubMed]
  21. Whitfield, L. Anesthesia and analgesia in laboratory animals, 3rd ed.; Dyson, M., jirkof, P., Lofgren, J., nunamaker, E., pang, D., Eds.; Elsevier: 230 park avenue, New York, NY 10169, USA, 2023; 788 pages hardback, ISBN 9780128222157. [Google Scholar]
  22. Stein, A.B.; Tiwari, S.; Thomas, P.; Hunt, G.; Levent, C.; Stoddard, M.F.; et al. Effects of anesthesia on echocardiographic assessment of left ventricular structure and function in rats. Basic Res. Cardiol. 2007, 102(1), 28–41. [Google Scholar] [CrossRef] [PubMed]
  23. Plante, E.; Lachance, D.; Roussel, E.; Drolet, M.C.; Arsenault, M.; Couet, J. Impact of anesthesia on echocardiographic evaluation of systolic and diastolic function in rats. J. Am. Soc. Echocardiogr. 2006, 19(12), 1520–5. [Google Scholar] [CrossRef] [PubMed]
  24. Redfors, B.; Shao, Y.; Omerovic, E. Influence of anesthetic agent, depth of anesthesia and body temperature on cardiovascular functional parameters in the rat. Lab Anim. 2014, 48(1), 6–14. [Google Scholar] [CrossRef] [PubMed]
  25. Droogmans, S.; Lauwers, R.; Cosyns, B.; Roosens, B.; Franken, P.R.; Weytjens, C.; et al. Impact of anesthesia on valvular function in normal rats during echocardiography. Ultrasound Med. Biol. 2008, 34(10), 1564–72. [Google Scholar] [CrossRef] [PubMed]
  26. Ruppert, M.; Korkmaz-Icöz, S.; Li, S.; Merkely, B.; Karck, M.; Radovits, T.; et al. Reverse electrical remodeling following pressure unloading in a rat model of hypertension-induced left ventricular myocardial hypertrophy. Hypertens. Res. 2017, 40(7), 637–45. [Google Scholar] [CrossRef] [PubMed]
  27. Cuijpers, I.; Carai, P.; Mendes-Ferreira, P.; Simmonds, S.J.; Mulder, P.; Miranda-Silva, D.; et al. The effect of different anaesthetics on echocardiographic evaluation of diastolic dysfunction in a heart failure with preserved ejection fraction model. Sci. Rep. 2020, 10(1), 15701. [Google Scholar] [CrossRef] [PubMed]
  28. Roth, D.M.; Swaney, J.S.; Dalton, N.D.; Gilpin, E.A.; Ross, J., Jr. Impact of anesthesia on cardiac function during echocardiography in mice. Am. J. Physiol. Heart Circ. Physiol. 2002, 282(6), H2134–40. [Google Scholar] [CrossRef] [PubMed]
  29. Percie du Sert, N.; Hurst, V.; Ahluwalia, A.; Alam, S.; Avey, M.T.; Baker, M.; et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. BMJ Open Sci. 2020, 4(1), e100115. [Google Scholar] [PubMed]
  30. Kokubo, M.; Uemura, A.; Matsubara, T.; Murohara, T. Noninvasive evaluation of the time course of change in cardiac function in spontaneously hypertensive rats by echocardiography. Hypertens. Res. 2005, 28(7), 601–9. [Google Scholar] [CrossRef] [PubMed]
  31. Bencze, M.; Behuliak, M.; Zicha, J. The impact of four different classes of anesthetics on the mechanisms of blood pressure regulation in normotensive and spontaneously hypertensive rats. Physiol. Res. 2013, 62(5), 471–8. [Google Scholar] [CrossRef] [PubMed]
Table 1. Rat Models of Cardiomyopathy.
Table 1. Rat Models of Cardiomyopathy.
Mechanism Model Application
Toxic (drug-induced) Doxorubicin-induced cardiomyopathy Study dilated cardiomyopathy, particularly chemotherapy-induced cardiotoxicity
Isoproterenol-induced cardiomyopathy Simulate acute ischemic-necrotic myocardial injury and hypertrophic cardiomyopathy
Genetic/Spontaneous Spontaneously hypertensive rats (SHR) Studies of long-term cardiac remodeling and hypertension-induced heart failure
Obese ZSF1 rats (HFpEF model) Study heart failure with preserved ejection fraction (HFpEF) and cardiometabolic disorders
Surgical Aortic ligation / Transverse aortic constriction (TAC) Simulate pressure-overload conditions such as arterial hypertension and aortic stenosis, leading to left ventricular hypertrophy and heart failure
Monocrotaline (MCT) model Induce pulmonary vascular injury leading to pressure overload and right ventricular hypertrophy
Metabolic Streptozotocin-induced diabetic cardiomyopathy Study diabetic cardiomyopathy independent of coronary artery disease or hypertension
Table 2. Anesthetic and Sedative Agents Commonly Used in Rat Echocardiography.
Table 2. Anesthetic and Sedative Agents Commonly Used in Rat Echocardiography.
Drug Pharmacological Mechanism Cardiovascular Effect
Isoflurane / Sevoflurane Positive allosteric modulator of GABA-A receptors, agonist of glycine receptors and potassium channels, antagonist of glutamate receptors Dose-dependent depression of the cardiovascular and respiratory systems
Ketamine NMDA receptor antagonist In healthy animals: central sympathetic stimulation and increased cardiac performance; in severely compromised cardiac function: potential negative inotropic effect; in combination with xylazine: decline in heart rate and cardiac output
Tiletamine Dissociative NMDA receptor antagonist (more potent and longer-acting than ketamine) In combination with zolazepam: significantly higher cardiac function index with elevated blood pressure
Xylazine Alpha-2 adrenergic receptor agonist Bradycardia and reduced cardiac output; when combined with ketamine, counteracts ketamine-induced sympathetic activation
Pentobarbital Positive allosteric modulator and agonist of GABA-A receptors Hypotension due to depression of central sympathetic activity and direct depression of myocardial contractility
Zolazepam
(benzodiazepine)
Positive allosteric modulator of GABA-A receptors Very weak to negligible negative effect on the cardiovascular system
Acepromazine Antagonism of central dopaminergic receptors, peripheral alpha-1 adrenergic blockade Vasodilation and reduction in arterial blood pressure
Table 3. Most commonly used anesthetic protocol for each cardiomyopathy model.
Table 3. Most commonly used anesthetic protocol for each cardiomyopathy model.
Cardiomyopathy Model Most Commonly Used Anesthetic Protocol
Doxorubicin-induced cardiomyopathy Ketamine-xylazine or isoflurane
Isoproterenol-induced cardiomyopathy Ketamine-xylazine (most common in standard toxicological studies), but isoflurane shows a unique, dose-dependent cardioprotective effect that directly alters the degree of induced dysfunction
TAC / pressure overload Isoflurane
Monocrotaline model Isoflurane
Aortic regurgitation Ketamine-xylazine and isoflurane
Streptozotocin-induced diabetic cardiomyopathy Ketamine-xylazine
Spontaneously hypertensive rat Isoflurane
HFpEF (ZSF1 model) Ketamine-xylazine
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.